Diagnostic biomarkers and therapeutic targets for pancreatic cancer
We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.
1. A method of treating a human with a tumor selected from the group consisting of pancreas, breast, biliary, lung, colon, and liver, comprising: administering a pancreatic cancer vaccine composition to the human whereby an immune response to regulatory subunit 12A of protein phosphatase 1 (PPP1R12A) and/or regulatory subunit 8 of the 26S proteasome (PSMC5) is raised and measured in the human.
2. The method of claim 1 wherein prior to said step of administering a sample of the tumor is tested and expression of PPP1R12A and/or PSMC5 on cell membranes of the tumor is detected.
3. The method of claim 1 wherein the vaccine is GM-CSF vaccine (GVAX).